ClinicalTrials.gg

Program

sumecigrel

Also written as “Vicagrel 6mg”, “Vicagrel” and “Vicagrel Capsules”.

Its studies are mostly in Acute Coronary Syndrome · Coronary Artery Disease, led by Jiangsu vcare pharmaceutical technology.

Furthest: phase 3, since Aug 28, 20248 company-led studies, 1 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu vcare pharmaceutical technology81 open or runningphase 3since Aug 28, 2024Jul 9, 2018Dec 30, 2026phase 3 · NCT06577519

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2018First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT03599284 · 279 enrolled · China
  2. Apr 24, 2019Phase 1 study in Healthy SubjectsNCT03942458 · 50 enrolled · China
  3. Oct 21, 2019Phase 1 study in Healthy Male AdultNCT04143750 · 6 enrolled · China
  4. Jun 8, 2021Phase 1 study in Acute Coronary SyndromeNCT04919551 · 24 enrolled · China
  5. Dec 14, 2021Phase 1 study in Acute Coronary SyndromeNCT05162053 · 128 enrolled · United States, China
  6. Nov 17, 2022Phase 1 study in Healthy SubjectsNCT05651074 · 20 enrolled · China
  7. Aug 28, 2024Phase 3 study in Acute Coronary SyndromeNCT06577519 · 1,000 planned · China
  8. Jul 7, 2025Phase 1 study in Acute Coronary SyndromeNCT07067775 · 18 enrolled · China

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Acute Coronary SyndromeNCT06577519

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07067775Acute Coronary Syndrome · China1CompletedAug 22, 202518
NCT06577519Acute Coronary Syndrome · China3RecruitingDec 30, 20261,000
NCT05651074Healthy Subjects · China1UNKNOWNFeb 202320
NCT05162053Acute Coronary Syndrome · United States, China1CompletedNov 3, 2022128
NCT04919551Acute Coronary Syndrome · China1CompletedOct 20, 202124
NCT04143750Healthy Male Adult · China1CompletedDec 29, 20196
NCT03942458Healthy Subjects · China1CompletedJun 28, 201950
NCT03599284Coronary Artery Disease · China2CompletedJun 11, 2019279

How it is read

Names in the registry

  • “Vicagrel 6mg”, 2 entries
  • “Vicagrel”, 1 entry
  • “Vicagrel Capsules”, 1 entry
  • “vicagrel Capsules”, 1 entry
  • “Vicagrel and omeprazole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.